
Federal Circuit Clarifies a Distinction Between Enablement for Patent Validity Under §112 and Enablement for Anticipation Under §102
In Agilent Technologies, Inc. v. Synthego Corp., No. 2023-2186 (Fed. Cir. June 11, 2025), the Federal Circuit affirmed the Patent Trial and Appeal Board’s (PTAB) decisions that invalidated all claims of two CRISPR-related patents owned by Agilent Technologies, Inc....